In August 2025, Lannett Company voluntarily recalled 8,544 bottles of lisdexamfetamine dimesylate capsules — a generic version of the well-known ADHD medication Vyvanse — after discovering that bottles labeled as 40 mg actually contained 30 mg capsules. The label mix-up meant that children and adults relying on the medication for attention deficit hyperactivity disorder were unknowingly receiving a lower dose than prescribed, putting them at risk for inadequate symptom control. The FDA classified it as a Class II recall, indicating that exposure could cause temporary or medically reversible adverse health effects, and by January 13, 2026, the agency confirmed the recall was completed.
But this was far from an isolated incident. A troubling pattern of pediatric drug recalls involving wrong doses, mislabeled strengths, and hidden ingredients has emerged in recent years, raising urgent questions for parents and caregivers — including those managing medications for loved ones with dementia-related behavioral symptoms. From infant ibuprofen with dangerously high concentrations to a children’s supplement laced with an unapproved growth hormone stimulator, the scope of these errors demands attention. This article examines the major recalls, explains the real-world risks they pose, and offers practical guidance for protecting vulnerable patients.
Table of Contents
- Which Pediatric Drugs Were Recalled for Containing the Wrong Dose?
- How Mislabeled Infant Medications Can Cause Permanent Harm
- Hidden Ingredients in Children’s Supplements — The iKids-Growth Recall
- What Parents and Caregivers Should Do When a Medication Is Recalled
- Why Wrong-Dose Errors Keep Happening in Drug Manufacturing
- When the Measuring Tool Is the Problem — The Robitussin and Dimetapp Recalls
- What These Recalls Mean for Vulnerable Populations Going Forward
- Conclusion
- Frequently Asked Questions
Which Pediatric Drugs Were Recalled for Containing the Wrong Dose?
The Lannett lisdexamfetamine recall is one of several cases where the medication inside the bottle did not match what the label promised. In a separate but equally concerning incident, Endo USA recalled a lot of clonazepam orally disintegrating tablets — lot number 550147301, with an expiration date of August 2026 — after discovering that tablets labeled as 0.125 mg actually contained 0.25 mg, double the intended strength. Clonazepam is a benzodiazepine prescribed for seizure disorders and panic attacks, and receiving twice the expected dose could cause excessive sedation, respiratory depression, or dangerous interactions with other medications. For older adults with dementia who may already be sensitive to sedatives, this kind of error is particularly alarming. Then there is the dissolution failure recall. OHM Laboratories, a division of Sun Pharmaceutical Industries, recalled multiple lots of lisdexamfetamine dimesylate spanning seven dosage strengths — from 10 mg all the way up to 70 mg — after the capsules failed dissolution testing.
In plain terms, the medication was not breaking down properly in the body, which meant patients were potentially not absorbing the therapeutic dose at all. The affected lots had expiration dates ranging from February 2026 through May 2026. Unlike a simple labeling error, a dissolution failure is harder for a patient or caregiver to detect because the pill looks correct and the label reads correctly. The only sign might be a gradual return of symptoms with no obvious explanation. What connects these cases is the gap between what a caregiver believes they are giving a patient and what the patient actually receives. Whether the dose is too low, too high, or simply not being absorbed, the consequences fall on the most vulnerable people in the chain — children, infants, and elderly patients who cannot easily advocate for themselves.
How Mislabeled Infant Medications Can Cause Permanent Harm
Among the most alarming recalls in recent years involved infant ibuprofen. Tris Pharma, Inc. expanded a voluntary nationwide recall of Ibuprofen Oral Suspension Drops, USP, 50 mg per 1.25 mL, after some units were found to contain up to 10 percent higher ibuprofen concentration than the label specified. Ten percent may not sound dramatic for an adult, but infants are far more susceptible to the effects of higher-potency drug levels. Their kidneys are still developing, their body weight is low, and their ability to metabolize and excrete medications is limited. The FDA warned that the elevated concentration could cause permanent NSAID-associated renal injury — meaning lasting kidney damage from what a parent thought was a standard dose of over-the-counter pain reliever. However, it is important to understand that not every bottle in a recalled lot necessarily contains the wrong concentration.
Recalls are issued when testing reveals that some units within certain batches fall outside acceptable limits. A parent who used a bottle from a recalled lot should not panic, but they should stop using the product, check for symptoms like decreased urination or unusual swelling, and consult their pediatrician. The risk is real, but it is probabilistic rather than certain. That distinction matters for anxious caregivers who may have already administered doses before learning about the recall. this case also illustrates a limitation of the recall system itself. The Tris Pharma recall covered multiple batches distributed to retailers nationwide, but there is no centralized way to push notifications to every parent who purchased the product. Unless a caregiver actively checks the FDA’s recall database or happens to see a news report, they may continue using a compromised product for weeks or months.
Hidden Ingredients in Children’s Supplements — The iKids-Growth Recall
Not all dosing problems come from pharmaceutical manufacturers. In one of the more unsettling cases, Agebox recalled 665 bottles of iKids-Growth Day Formula and an undisclosed number of Night Formula bottles after FDA lab testing confirmed the presence of undeclared ibutamoren, also known as MK-677. Ibutamoren is an unapproved growth hormone stimulator that has never been authorized by the FDA for any medical use. It was being given to children through what was marketed as a dietary supplement. The timeline reveals how slowly enforcement can move. The FDA first issued a consumer alert about iKids-Growth in September 2025, then sent a warning letter to the company in December 2025, and did not post the recall enforcement report until March 3, 2026 — roughly six months after the initial alert.
During that window, the product remained available for purchase on the company’s website and on Amazon. The health risks associated with ibutamoren include increased appetite, fluid retention, fatigue, muscle aches, blood sugar and insulin fluctuations, and a potential increased risk of congestive heart failure. These are not trivial side effects, and they were being introduced into children’s bodies without any informed consent from their parents. For families caring for someone with dementia, this case serves as a cautionary tale about supplements more broadly. The supplement industry operates under far less regulatory scrutiny than pharmaceuticals, and products marketed for cognitive health, memory support, or brain function may carry similar risks of undeclared or unapproved ingredients. If a supplement sounds too good to be true, it probably warrants a closer look at its ingredient transparency and FDA compliance history.
What Parents and Caregivers Should Do When a Medication Is Recalled
The first step after learning about a recall is deceptively simple: check whether you have the product. This means looking at the lot number and expiration date on the packaging and comparing it against the specific lots listed in the FDA’s recall announcement. Not all units of a given medication are recalled — typically only certain lots manufactured during a particular window are affected. If you confirm that you have an affected product, stop administering it immediately and contact your prescribing physician or pharmacist for a replacement. The tradeoff that many caregivers face, however, is between the risk of the recalled product and the risk of going without the medication entirely. For a child whose ADHD symptoms are well-controlled on lisdexamfetamine, abruptly stopping the medication while waiting for a replacement can lead to significant behavioral and academic disruption.
Similarly, an older adult taking clonazepam for seizure management cannot simply skip doses without risking breakthrough seizures. In these situations, the right move is to call the prescriber before making any changes. A doctor may be able to call in an alternative medication from a different manufacturer, adjust the dosing of what remains, or provide guidance on safe tapering. The worst approach is for a caregiver to attempt their own dose adjustments without medical input — precisely the kind of dangerous self-correction the FDA warned about in the Lannett recall. Pharmacists are an underutilized resource in these situations. They can often check whether a specific bottle came from a recalled lot, suggest therapeutic alternatives that are in stock, and flag drug interactions that a substitute medication might introduce.
Why Wrong-Dose Errors Keep Happening in Drug Manufacturing
Manufacturing errors that lead to wrong-dose products stem from several sources, and understanding them reveals why this problem is unlikely to disappear. The Lannett lisdexamfetamine recall, for instance, was caused by a labeling mix-up — the wrong labels were applied to bottles during the packaging process. The clonazepam recall involved the wrong tablets being placed into correctly labeled containers. The Tris Pharma ibuprofen recall reflected a quality control failure in the formulation itself, where the active ingredient concentration exceeded specifications. One systemic factor is the growth of generic drug manufacturing.
As patents expire on brand-name medications like Vyvanse, multiple generic manufacturers enter the market, each running their own production lines. This expands access and reduces costs, which is broadly beneficial, but it also multiplies the number of facilities where errors can occur. The FDA inspects these facilities, but inspections are periodic rather than continuous, and some manufacturers operate overseas where inspection logistics are more challenging. A limitation worth noting is that the FDA’s recall classification system, while useful, can create a false sense of security. A Class II recall — the category assigned to the Lannett lisdexamfetamine case — is defined as a situation where exposure may cause “temporary or medically reversible adverse health effects.” That language sounds reassuring. But for a child who loses weeks of academic progress because their ADHD medication was underdosed, or for a dementia patient who suffers a fall due to excessive sedation from a double-strength benzodiazepine, the consequences may be technically reversible yet profoundly disruptive.
When the Measuring Tool Is the Problem — The Robitussin and Dimetapp Recalls
Sometimes the medication itself is fine, but the tool used to measure it is defective. GSK Consumer Healthcare recalled two lots of Children’s Robitussin Honey Cough and Chest Congestion DM and one lot of Children’s Dimetapp Cold and Cough because the dosing cups included with these products were missing the 5 mL and 10 mL graduation markings. Without those lines on the cup, a parent pouring medicine at three in the morning for a coughing child is essentially guessing the dose.
The result could be too little medication to be effective or too much medication, leading to side effects like drowsiness or gastrointestinal upset. This recall is a useful reminder that dosing accuracy depends on the entire system — the drug, the label, and the delivery device. Caregivers should keep a set of clearly marked oral syringes at home, especially when administering liquid medications to children or to adults with swallowing difficulties common in later-stage dementia. An oral syringe is more precise than a dosing cup under the best of circumstances and far more reliable than a cup with no markings at all.
What These Recalls Mean for Vulnerable Populations Going Forward
The pattern across these recalls points to a broader reality: medication safety is not guaranteed at the point of purchase. It requires active vigilance from caregivers, transparent communication from manufacturers, and faster enforcement from regulators. The six-month gap between the FDA’s first alert about iKids-Growth and the formal recall posting is an example of a system that moves too slowly when children’s health is at stake.
For those in the dementia care community, these recalls carry additional weight. Many individuals with dementia take multiple medications, and their caregivers are often managing complex regimens under significant stress. A wrong-dose error in one medication can cascade into symptoms that mimic disease progression, trigger unnecessary medication changes, or cause adverse events that lead to hospitalization. Staying informed about recalls, maintaining a relationship with a trusted pharmacist, and approaching supplements with healthy skepticism are not optional extras — they are essential parts of safe caregiving.
Conclusion
The recalls discussed here — from Lannett’s mislabeled ADHD medication and Endo USA’s double-strength clonazepam tablets to Tris Pharma’s overly concentrated infant ibuprofen and Agebox’s supplement laced with an unapproved drug — represent different types of failures with a common thread. In each case, a vulnerable patient received something other than what their caregiver intended to give them.
The consequences ranged from inadequate symptom control to potential permanent organ damage. Caregivers should sign up for FDA recall alerts, verify lot numbers when filling prescriptions, and never hesitate to call a pharmacist or physician when something about a medication seems off — whether it is a change in pill appearance, an unexpected shift in symptoms, or a news report about a product they use. Medication errors at the manufacturing level are not within a caregiver’s control, but catching them quickly and responding appropriately is.
Frequently Asked Questions
How do I check if my child’s medication has been recalled?
Visit the FDA’s drug recall database at fda.gov/drugs/drug-safety-and-availability/drug-recalls and search by drug name or manufacturer. Compare the lot number and expiration date on your product’s packaging against the specific lots listed in the recall notice.
What should I do if I already gave my child a recalled medication?
Do not panic. Contact your child’s pediatrician or call Poison Control at 1-800-222-1222. Monitor for any unusual symptoms and bring the product packaging with you to any medical visit so the provider can identify the exact lot and dosage involved.
Are generic medications less safe than brand-name drugs?
Not inherently. Generics must meet the same FDA standards for active ingredient concentration, purity, and bioequivalence. However, the proliferation of generic manufacturers means more production facilities and more opportunities for packaging and formulation errors to occur.
Can a wrong-dose medication error affect someone with dementia?
Yes, and often more severely than in younger, healthier patients. Older adults with dementia may metabolize medications differently, take multiple drugs that interact with each other, and be unable to report symptoms of over- or under-dosing. Caregivers should be especially attentive to any changes in behavior, alertness, or physical function after starting or refilling a medication.
How long does it typically take for the FDA to complete a drug recall?
Timelines vary significantly. The Lannett lisdexamfetamine recall was announced in August 2025 and confirmed completed by January 2026 — about five months. The iKids-Growth enforcement action took roughly six months from initial alert to formal recall posting. During these periods, affected products may still be in consumers’ homes.
